TY - JOUR
T1 - A Cohort study of STMN1 expression in colorectal cancer
T2 - Body mass index and prognosis
AU - Ogino, Shuji
AU - Nosho, Katsuhiko
AU - Baba, Yoshifumi
AU - Kure, Shoko
AU - Shima, Kaori
AU - Irahara, Natsumi
AU - Toyoda, Saori
AU - Chen, Li
AU - Kirkner, Gregory J.
AU - Wolpin, Brian M.
AU - Chan, Andrew T.
AU - Giovannucci, Edward L.
AU - Fuchs, Charles S.
PY - 2009/8
Y1 - 2009/8
N2 - OBJECTIVES: STMN1 (stathmin or oncoprotein-18) destabilizes microtubules and reorganizes cytoskeleton, and functions in cell cycle progression and cell migration. STMN1 activity is influenced by p53, p27, and the PI3K/AKT pathway. However, its prognostic significance in colon cancer is uncertain.METHODS: Utilizing 546 colorectal cancers (stage I-IV) from two independent prospective cohort studies (the Nurses Health Study and Health Professionals Follow-up Study), STMN1 expression was detected in 297 (54%) tumors by immunohistochemistry. Cox proportional hazard models computed hazard ratios (HRs) of mortality, adjusted for clinical and tumoral features, including microsatellite instability (MSI), CpG island methylation phenotype (CIMP), LINE-1 hypomethylation, KRAS, BRAF, PIK3CA, p53, p21, p27, cyclin D1, Β-catenin, fatty acid synthase, FASN, and COX-2.RESULTS:Five-year colorectal cancer-specific survival was 78% in STMN1-positive patients and 76% in STMN1-negative patients (log-rank P0.30). STMN1-positivity was not significantly associated with cancer-specific survival in univariate analysis with HR of 0.82 (95% confidence interval (CI), 0.59-1.14), which became significant in multivariate analysis (adjusted HR0.60; 95% CI, 0.41-0.87; P0.0078). Notably, the prognostic effect of obesity (body mass index, BMI3≥0 kg/m2) significantly differed by STMN1 (Pinteraction 0.005). Obesity was associated with high cancer-specific mortality among STMN1-positive patients (adjusted HR2.36; 95% CI, 1.18-4.69), whereas obesity was not associated with high mortality among STMN1-negative patients (adjusted HR0.51; 95% CI, 0.24-1.07).CONCLUSIONS:STMN1 overexpression in colorectal cancer is independently associated with improved survival. The adverse prognostic effect of obesity was limited to patients with STMN1-positive tumors. Our findings suggest the presence of a tumor (STMN1)-host (BMI) interaction that potentially determines clinical outcome.
AB - OBJECTIVES: STMN1 (stathmin or oncoprotein-18) destabilizes microtubules and reorganizes cytoskeleton, and functions in cell cycle progression and cell migration. STMN1 activity is influenced by p53, p27, and the PI3K/AKT pathway. However, its prognostic significance in colon cancer is uncertain.METHODS: Utilizing 546 colorectal cancers (stage I-IV) from two independent prospective cohort studies (the Nurses Health Study and Health Professionals Follow-up Study), STMN1 expression was detected in 297 (54%) tumors by immunohistochemistry. Cox proportional hazard models computed hazard ratios (HRs) of mortality, adjusted for clinical and tumoral features, including microsatellite instability (MSI), CpG island methylation phenotype (CIMP), LINE-1 hypomethylation, KRAS, BRAF, PIK3CA, p53, p21, p27, cyclin D1, Β-catenin, fatty acid synthase, FASN, and COX-2.RESULTS:Five-year colorectal cancer-specific survival was 78% in STMN1-positive patients and 76% in STMN1-negative patients (log-rank P0.30). STMN1-positivity was not significantly associated with cancer-specific survival in univariate analysis with HR of 0.82 (95% confidence interval (CI), 0.59-1.14), which became significant in multivariate analysis (adjusted HR0.60; 95% CI, 0.41-0.87; P0.0078). Notably, the prognostic effect of obesity (body mass index, BMI3≥0 kg/m2) significantly differed by STMN1 (Pinteraction 0.005). Obesity was associated with high cancer-specific mortality among STMN1-positive patients (adjusted HR2.36; 95% CI, 1.18-4.69), whereas obesity was not associated with high mortality among STMN1-negative patients (adjusted HR0.51; 95% CI, 0.24-1.07).CONCLUSIONS:STMN1 overexpression in colorectal cancer is independently associated with improved survival. The adverse prognostic effect of obesity was limited to patients with STMN1-positive tumors. Our findings suggest the presence of a tumor (STMN1)-host (BMI) interaction that potentially determines clinical outcome.
UR - http://www.scopus.com/inward/record.url?scp=68349158956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68349158956&partnerID=8YFLogxK
U2 - 10.1038/ajg.2009.281
DO - 10.1038/ajg.2009.281
M3 - Article
C2 - 19513025
AN - SCOPUS:68349158956
SN - 0002-9270
VL - 104
SP - 2047
EP - 2056
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 8
ER -